Fidler S - Search Results

1

Structured observations reveal slow HIV-1 CTL escape.

Roberts HE, Hurst J, Robinson N, Brown H, Flanagan P, Vass L, Fidler S, Weber J, Babiker A, Phillips RE, McLean AR, Frater J; SPARTAC trial investigators. Roberts HE, et al. Among authors: fidler s. PLoS Genet. 2015 Feb 2;11(2):e1004914. doi: 10.1371/journal.pgen.1004914. eCollection 2015 Feb. PLoS Genet. 2015. PMID: 25642847 Free PMC article.

2

CD4+ T-cell recognition of diverse clade B HIV-1 isolates.

Fernandez MH, Fidler SJ, Pitman RJ, Weber JN, Rees AD. Fernandez MH, et al. Among authors: fidler sj. AIDS. 1997 Mar;11(3):281-8. doi: 10.1097/00002030-199703110-00004. AIDS. 1997. PMID: 9147418

3

Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection.

Fidler S, Oxenius A, Brady M, Clarke J, Cropley I, Babiker A, Zhang HT, Price D, Phillips R, Weber J. Fidler S, et al. AIDS. 2002 Oct 18;16(15):2049-54. doi: 10.1097/00002030-200210180-00010. AIDS. 2002. PMID: 12370504 Clinical Trial.

4

HIV-1-specific CD4+ T lymphocyte turnover and activation increase upon viral rebound.

Scriba TJ, Zhang HT, Brown HL, Oxenius A, Tamm N, Fidler S, Fox J, Weber JN, Klenerman P, Day CL, Lucas M, Phillips RE. Scriba TJ, et al. Among authors: fidler s. J Clin Invest. 2005 Feb;115(2):443-50. doi: 10.1172/JCI23084. J Clin Invest. 2005. PMID: 15668739 Free PMC article.

5

Ultrasensitive detection and phenotyping of CD4+ T cells with optimized HLA class II tetramer staining.

Scriba TJ, Purbhoo M, Day CL, Robinson N, Fidler S, Fox J, Weber JN, Klenerman P, Sewell AK, Phillips RE. Scriba TJ, et al. Among authors: fidler s. J Immunol. 2005 Nov 15;175(10):6334-43. doi: 10.4049/jimmunol.175.10.6334. J Immunol. 2005. PMID: 16272285

6

Resistance to HIV drugs in UK may be lower in some areas.

Fox JM, Fidler S, Weber J. Fox JM, et al. Among authors: fidler s. BMJ. 2006 Jan 21;332(7534):179-80. doi: 10.1136/bmj.332.7534.179-c. BMJ. 2006. PMID: 16424507 Free PMC article. No abstract available.

7

Comparative potency of three antiretroviral therapy regimes in primary HIV infection.

Fidler S, Fraser C, Fox J, Tamm N, Griffin JT, Weber J. Fidler S, et al. AIDS. 2006 Jan 9;20(2):247-52. doi: 10.1097/01.aids.0000200530.71737.75. AIDS. 2006. PMID: 16511418 Clinical Trial.

8

Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART.

Sutherland R, Yang H, Scriba TJ, Ondondo B, Robinson N, Conlon C, Suttill A, McShane H, Fidler S, McMichael A, Dorrell L. Sutherland R, et al. Among authors: fidler s. AIDS. 2006 Apr 4;20(6):821-9. doi: 10.1097/01.aids.0000218545.31716.a4. AIDS. 2006. PMID: 16549965

9

Prevalence of primary genotypic resistance in a UK centre: Comparison of primary HIV-1 and newly diagnosed treatment-naive individuals.

Fox J, Hill S, Kaye S, Dustan S, McClure M, Fidler S, Mackie NE. Fox J, et al. Among authors: fidler s. AIDS. 2007 Jan 11;21(2):237-9. doi: 10.1097/01.aids.0000247577.26375.ef. AIDS. 2007. PMID: 17197816

10

Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort.

Fidler S, Fox J, Touloumi G, Pantazis N, Porter K, Babiker A, Weber J. Fidler S, et al. AIDS. 2007 Jun 19;21(10):1283-91. doi: 10.1097/QAD.0b013e3280b07b5b. AIDS. 2007. PMID: 17545704

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

376 results

Search Page